DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)

NCT05966064 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Fibrous Dysplasia
McCune Albright Syndrome

Interventions

DRUG: Denosumab 120 Mg/1.7 Ml Inj
DRUG: Placebo

Sponsor

Natasha Appelman-Dijkstra